Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Begoña Mellado Gonzalez"'
Autor:
Miguel A. Climent, Albert Font, Ignacio Durán, Javier Puente, María José Méndez-Vidal, María Isabel Sáez, Carmen Santander Lobera, Jóse Ángel Arranz Arija, Aranzazu González-del-Alba, Alfredo Sánchez-Hernandez, Maria Jose Juan Fita, Emilio Esteban, Teresa Alonso-Gordoa, Begoña Mellado Gonzalez, Pablo Maroto, Martín Lázaro-Quintela, Javier Cassinello-Espinosa, Begoña Pérez-Valderrama, Carmen Garcias, Daniel Castellano
We aimed to compare the efficacy and safety of maintaining or withdrawing abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer who had experienced cancer progression to this treatment and were beg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::059cf185aa13df31a0c4383267bf4b5b
https://hdl.handle.net/10668/22179
https://hdl.handle.net/10668/22179
Autor:
Oscar Reig Torras, Natalia Jiménez, Marta Garcia de Herreros, Caterina Aversa, Mercedes Marin, Laura Ferrer, Leonardo Rodriguez-Carunchio, Isabel Trias, Laia Fernandez-Mañas, Samuel García-Esteve, Albert Font Pous, Alejo Rodriguez-Vida, Montserrat Domenech-Santasusana, Mariona Figols, Miguel Ángel Climent, Sara Cros Costa, Isabel Chirivella, Daniel Herrero Rivera, Cristina Suárez, Begoña Mellado-Gonzalez
Publikováno v:
Journal of Clinical Oncology. 41:236-236
236 Background: Alterations on the tumor suppressor genes (TSG) RB1, PTEN and TP53 are associated with treatment resistance and aggressive clinical evolution of prostate cancer patients (pts). We developed and assessed the role of a TSG gene expressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::150f96adcfc96ebc7f778733663933e6
https://doi.org/10.1200/jco.2023.41.6_suppl.236
https://doi.org/10.1200/jco.2023.41.6_suppl.236
Autor:
Maria Jose Juan FITA, Urbano Anido Herranz, Maria Jose Mendez Vidal, Regina Gironés, Begoña Mellado-Gonzalez, José Manuel Sepulveda Sánchez, Carlos Alvarez-Fernandez, Miguel Ángel Climent, Lucia Heras
Publikováno v:
Journal of Clinical Oncology. 41:168-168
168 Background: Prostate cancer is the second most common cancer in men. A number of important systemic therapies have been developed to treat mCRPC and now comprise the current therapeutic landscape. Docetaxel became the first systemic therapy to im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e53700cfd08120d2599b6e4483fb21f
https://doi.org/10.1200/jco.2023.41.6_suppl.168
https://doi.org/10.1200/jco.2023.41.6_suppl.168
Autor:
Mariona Calvo, Konstantin Penkov, Alexander I. Spira, Irene Moreno Candilejo, Neal D. Shore, Tian Zhang, Begoña Mellado-Gonzalez, Teresa Alonso Gordoa, Luis Paz-Ares Rodriguez, Stefano R. Tarantolo, Juan José Soto, Robert S. Alter, Claudia Andreu-Vieyra, Timothy Bowler, Arnab K Maity, Subramanian Hariharan, Michael Thomas Schweizer
Publikováno v:
Journal of Clinical Oncology. 41:TPS282-TPS282
TPS282 Background: Enhancer of zeste homolog 2 (EZH2) encodes the histone methyltransferase component of the polycomb repressive complex-2, inducing transcriptional silencing of target genes, and is altered in cancers such as follicular lymphoma (FL)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9abe4fd25b9c1717a2d8695a870fd57
https://doi.org/10.1200/jco.2023.41.6_suppl.tps282
https://doi.org/10.1200/jco.2023.41.6_suppl.tps282